Answer the following practice question Now that Inclisiran has finally gotten FDA approval, for each patient described below (1-4), choose two patients (1-4) forwhom you are likely to prescribe Inclisiran and two for whom you are less likely to prescribe Inclisiran. For eachcase/patient, explain why you will ór will NOT prescribe Inclisiran at this moment. Information on each patient is below:1. Homozygous familial hypercholesterolemia (FH) patient2. Heterozygous FH patient3. Patient with hypercholesterolemia who cannot tolerate statins and is being treated with ezetimibe4. Patient with hypercholesterolemia who cannot tolerate statins and is being treated with PCSK9 antibodies.

The FDA recently approved Inclisiran, a new lipid-lowering agent. It is a small interfering RNA…

Answered: Now that Inclisiran has finally gotten…

Curren'S Math For Meds: Dosages & Sol

11th Edition

ISBN:9781305143531

Author:CURREN

Publisher:CURREN

Chapter15: Adult And Pediatric Dosages Based On Body Weight

Section: Chapter Questions

Problem 8.7P

See similar textbooks

Similar questions

Pharmacodynamic (PD) Response Biomarkers Instructions Group (https://www.ncbi.nlm.nih.gov/books/NBK326791/), a biomarker is used to show that a biological response has occurred in an individual who has been exposed to a medical product or an environmental agent. Match the pharmacodynamic/response biomarker on the left, with the related you can use internet search, FDA According to the FDA-NIH Biomarker Working treatment/disease on the right. Please note that and NIH websites, as well as the on-line library resources. Sweat chloride Response to warfarin treatment International Effect of enzyme replacement therapy for patients with mucopolysaccharidosis type 1 normalized ratio (INR) Response to a B-lymphocyte stimulator inhibitor in patients with systemic lupus erythematosus Viral load Urinary level of glycosaminoglycans Response to cystic fibrosis transmembrane regulator (CFTR) potentiating agents in patients with cystic fibrosis Blood pressure Response to antihyperglycemic agents or…
hi, can I please get help on a case study on nueroanatomy I have been struggling for a couple of hours now and can't seem to understand the study to answer the following questions. is there any way or format that i can get help. I would really appreciate it. thanks! 1. Based on the information in the case, what is the most likely neuroanatomic location for a single lesion that can explain all of the patient’s symptoms and signs? In your own words, explain how you arrived at that localization. 2.What are some possibilities for the nature of the lesion (e.g., stroke, tumor, trauma, etc.)? In your own words, explain your rationale for these options. 3. How does the laboratory data and neuroimaging demonstrate the actual lesion for the patient? Describe how you interpret the data in your own words. 4.How was the patient was treated, and how did they subsequently fare? Describe the treatment plan in your own words.
What does the acronym TPA stand for and how is TPA used in diagnostic medicine? Explain briefly.
Mrs. Anderson, a 45-year-old woman with a history of chronic back pain, has been taking X as prescribed by her rheumatologist for the past eight months. During a routine check-up, her liver function tests revealed significantly elevated liver enzymes. She has not experienced any noticeable symptoms but is now being closely monitored for potential liver-related issues. 1. Define the concept of signal detection in pharmacoepidemiology and explain its role in identifying potential adverse drug reactions. Discuss the importance of signal detection in ensuring the safety of pharmaceutical products in the post-marketing phase. 2. Propose a pharmacoepidemiological study design to confirm or refute the signal of hepatotoxicity associated with X. Consider factors such as study population, exposure definition, and outcome measures. Discuss the strengths and limitations of your chosen study design. 3. Outline the methods and data sources that could be used to collect information on…
This is homework not a test! From NTSA case study https://static.nsta.org/case_study_docs/case_studies/cystic_fibrosis.pdf Please help with questions 2, 3 and 4 of part four 2. "The successful use of gene therapy to cure SCID syndrome (2000) is hoped to be a permanent cure for those patients because a good copy of the problem gene was inserted into the patients' blood stem cells in the bone marrow (hematopoietic stem cells). Once white blood cells enter the blood stream they have a limited life span, on the order of a few week to months. The blood stem cells are the cells that create more white blood cells to replace those that are lost. If the gene was only inserted into the circulating mature white blood cells, the patient would only be temporarily cured until those cells were used up or died." The current gene therapy approaches to cure CF involve inserting a functional CFTR gene into the mature epithelial cells of the lungs. In light of the preceding paragraph, do you think that…
Filipina’s 3-year-old daughter, Manila, was brought to a clinic. The doctor diagnosed Manila with a severe dry cough. A mucolytic solution was prescribed and to be administered for seven days. The prescription states, “Mucolytic, XYZ Brand, 60 ml, dosage-1 teaspoon 1 hour before a meal, 3x a day”. Now, Filipina is skeptical of the dosage mentioned in the prescription regarding the proper amount of medicine to be administered to her daughter. If you are Filipina, how are you going to approach the case to make sure that your daughter will not have an overdose or underdose of the medicine prescribed? Apply the principle of accuracy and precision in the problem.
The remains of nine human beings were found in a site, degree of bone development and presence of Y chromosome DNA suggest four adult females (A, B, C & D), two adult males (E, F) and three juvenile females. Their DNA was available for testing. The gel pattern obtained for one SSR probe is shown in the figure below. The bands are numbered in order of increasing electrophoretic mobility. Adult O Adult O Juvenile Y A B C D E F G H I 1 -2 3. 9. 8. 10 Which of the following can you conclude from the results? Select all that apply Female C could be the biological parent of the three juvenile females OMale F could be the biological parent of the three juvenile females Female D could be the biological parent of the three juvenile females Male E could be the biological parent of the three juvenile females
1) COVID-19 a. Should there be clinical trails performed by agents (institutions) outside the very drug companies that manufacture them? b. Which factors influence the form of treatment in any given nation (example, amount of moeny, profits to be made, accessibility of the treatment, etc.) c. Which type od approaches you think may work the best in form of minimizing COVID-19 infections and the resulting side effects
(c) Molnupiravir has not been approved but has been authorized for emergency use by the FDA under an EUA to treat mild to moderate COVID-19 infection. Briefly explain this decision made by FDA based on the knowledge of clinical trials. (d) Both drugs are not allowed to be prescribed to person under 18 years old due to insufficient clinical data. Why is it necessary to separately conduct clinical trials for a younger age group?
Hello good day, I am having a problem answering this question and I need your help on this. Hoping for a response and thank you In each chosen disease, pls. supply the information below: So I've chosen "Phenylketonuria (PKU)", so I need a short description, its pathophysiology, laboratory diagnosis, and Treatment and Prevention of my chosen disease. a. Short Description b. Pathophysiology c. Laboratory Diagnosis d. Treatment and Prevention
During a home visit , Magdalena who is multigravida at 32 weeks ' gestation , tells the Nurse Marina that she craves and often eats laundry starch for lunch and usually has bowl of soup for supper Total weight gain to date has been 12 ( 5kg). A priority nursing diagnosis for the patent is: a. Altered parenting related to single status b.Noncompliance to insufficient resources c.Altered nutrition less than body requirements , related to pica d.Ineffective individual coping related to pregnancy
Mrs. Anderson, a 45-year-old woman with a history of chronic back pain, has been taking X as prescribed by her rheumatologist for the past eight months. During a routine check-up, her liver function tests revealed significantly elevated liver enzymes. She has not experienced any noticeable symptoms but is now being closely monitored for potential liver-related issues. 2. Propose a pharmacoepidemiological study design to confirm or refute the signal of hepatotoxicity associated with X. Consider factors such as study population, exposure definition, and outcome measures. Discuss the strengths and limitations of your chosen study design? Outline the methods and data sources that could be used to collect information on hepatotoxicity in patients using X.? Discuss how the findings of the study could have regulatory implications. If a significant association is identified, explore how regulatory agencies might implement other measures to ensure patient safety.? Develop communication…

SEE MORE QUESTIONS

Recommended textbooks for you

Curren'S Math For Meds: Dosages & Sol

Nursing

ISBN:

9781305143531

Author:

CURREN

Publisher:

Cengage

Human Heredity: Principles and Issues (MindTap Co…

Biology

ISBN:

9781305251052

Author:

Michael Cummings

Publisher:

Cengage Learning

Curren'S Math For Meds: Dosages & Sol

Nursing

ISBN:

9781305143531

Author:

CURREN

Publisher:

Cengage

Human Heredity: Principles and Issues (MindTap Co…

Biology

ISBN:

9781305251052

Author:

Michael Cummings

Publisher:

Cengage Learning

SEE MORE TEXTBOOKS